ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
About this item
Full title
Author / Creator
Pospisilova, S , Gonzalez, D , Malcikova, J , Trbusek, M , Rossi, D , Kater, A P , Cymbalista, F , Eichhorst, B , Hallek, M , Döhner, H , Hillmen, P , van Oers, M , Gribben, J , Ghia, P , Montserrat, E , Stilgenbauer, S , Zenz, T , on behalf of the European Research Initiative on CLL (ERIC) and European Research Initiative on CLL (ERIC)
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Recent evidence suggests that – in addition to 17p deletion –
TP53
mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a
TP53
mutation in the absence of 17p deletion. The...
Alternative Titles
Full title
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
Authors, Artists and Contributors
Author / Creator
Gonzalez, D
Malcikova, J
Trbusek, M
Rossi, D
Kater, A P
Cymbalista, F
Eichhorst, B
Hallek, M
Döhner, H
Hillmen, P
van Oers, M
Gribben, J
Ghia, P
Montserrat, E
Stilgenbauer, S
Zenz, T
on behalf of the European Research Initiative on CLL (ERIC)
European Research Initiative on CLL (ERIC)
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1028031417
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1028031417
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2012.25
